Dual-listed AFT Pharmaceuticals has reported strong earnings growth for the half-year with rising sales of its patented Maxigesic pain relief medicine in global markets and over-the-counter sales in Australasia.
Group operating revenue for the six months to September 30 rose 22% to $46.9 million
Want to read more? It's easy.
Choose your best value subscription option
Student
Exclusive offer for uni students studying at a New Zealand university (valued at $499).
